HanAll Biopharma Posts 920 Million Won Operating Loss Last Year, Swings to Deficit
HanAll Biopharma announced on the 21st that, on a consolidated basis, it posted an operating loss of 920 million won last year, turning to a deficit according to provisional figures.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Revenue reached 155.2 billion won, up 11.7% from the previous year. The net loss widened to 5.6 billion won. The operating loss for the fourth quarter was 2 billion won, turning to a deficit compared to an operating profit of 2.7 billion won in the same period of the previous year. For the quarter, revenue and net loss were 37.5 billion won and 6.2 billion won, respectively.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.